[HTML][HTML] Systemic and local immunosuppression in glioblastoma and its prognostic significance
AA Stepanenko, AO Sosnovtseva, MP Valikhov… - Frontiers in …, 2024 - frontiersin.org
The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy,
critically depends on the activity of the host immune cells. However, various local and …
critically depends on the activity of the host immune cells. However, various local and …
[HTML][HTML] Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review
Hepatocellular carcinoma (HCC), the most common primary liver malignancy and the sixth
most common cancer globally, remains fatal for many patients with inappropriate responses …
most common cancer globally, remains fatal for many patients with inappropriate responses …
[HTML][HTML] Neutrophil-to-lymphocyte ratio (NLR) predicts mortality in hospitalized geriatric patients independent of the admission diagnosis: a multicenter prospective …
M Di Rosa, J Sabbatinelli, L Soraci… - Journal of Translational …, 2023 - Springer
Abstract Background The Neutrophil-to-lymphocyte ratio (NLR) is a marker of poor
prognosis in hospitalized older patients with different diseases, but there is still no …
prognosis in hospitalized older patients with different diseases, but there is still no …
[HTML][HTML] MAD2L2, a key regulator in ovarian cancer and promoting tumor progression
K Xu, X Zheng, H Shi, J Ou, H Ding - Scientific Reports, 2024 - nature.com
Ovarian cancer (OVCA), a prevalent gynecological malignancy, ranks as the fourth most
common cancer among women. Mitotic Arrest Deficient 2 Like 2 (MAD2L2), a chromatin …
common cancer among women. Mitotic Arrest Deficient 2 Like 2 (MAD2L2), a chromatin …
[HTML][HTML] Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
A Sugimoto, H Kaneda, N Yoshimoto, K Nagata… - Scientific Reports, 2024 - nature.com
The usefulness of the derived neutrophil-to-lymphocyte ratio (dNLR) and its dynamics
before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear …
before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear …
Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses
H Wang, R Yang, D Liu, W Li - International Immunopharmacology, 2024 - Elsevier
Abstract Background The Neutrophil-to-lymphocyte ratio (NLR) holds relevance in cancer
immunotherapy outcomes, yet its validation remains limited. Thus, we conducted an …
immunotherapy outcomes, yet its validation remains limited. Thus, we conducted an …
Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities
Simple Summary Non-small cell lung cancer (NSCLC) is a common diagnosis from which
many patients die. Blood tests reflecting systemic inflammation are routinely collected in the …
many patients die. Blood tests reflecting systemic inflammation are routinely collected in the …
[HTML][HTML] Association between the neutrophil-to-lymphocyte ratio and in-hospital mortality in patients with chronic kidney disease and coronary artery disease in the …
J Luo, Y Zhou, Y Song, D Wang, M Li, X Du… - European Journal of …, 2024 - Springer
The objective of this study was to investigate the correlation between neutrophil-to-
lymphocyte ratios (NLR) and the risk of in-hospital death in patients admitted to the intensive …
lymphocyte ratios (NLR) and the risk of in-hospital death in patients admitted to the intensive …
[HTML][HTML] Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta …
S Hou, D Song, Y Zang, R Hao, L Li, J Zhu - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Objectives The prognostic relevance of the platelet-to-lymphocyte ratio (PLR) in gastric
cancer (GC) patients undergoing immune checkpoint inhibitor (ICI) treatment remains …
cancer (GC) patients undergoing immune checkpoint inhibitor (ICI) treatment remains …
[HTML][HTML] Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with …
K Matsumoto, Y Yamamoto, T Shiroyama, T Kuge… - Targeted Oncology, 2024 - Springer
Background Chemoimmunotherapy is a standard treatment for advanced non-small-cell
lung cancer (NSCLC). However, data on clinical predictive factors remain scarce. Objective …
lung cancer (NSCLC). However, data on clinical predictive factors remain scarce. Objective …